Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.

Marco Matucci-CerinicYannick AllanoreArthur KavanaughMaya H BuchHendrik Schulze-KoopsEugeniusz J KucharzHeike WoehlingGoran BabicJohann PoetzlAdanna DavisArnd Schwebig

Published in: RMD open (2018)

NCT02638259.

Keyphrases

phase iii
placebo controlled
rheumatoid arthritis
double blind
open label
clinical trial
ankylosing spondylitis
phase ii
disease activity
rheumatoid arthritis patients
study protocol
juvenile idiopathic arthritis
interstitial lung disease
early onset